Erratum: Prevalence of CYP2C9 polymorphisms in the south of Europe (Pharmacogenomics Journal (2009) DOI: 10.1038/tpj.2009.16));Prevalence of CYP2C9 polymorphisms in the south of Europe

Pharmacogenomics Journal

Volumn 9, Issue 5, 2009, Pages 306-310

  Sánchez Diz, Paula ^a   Estany Gestal, Ana ^a   Aguirre, Carmelo ^b   Blanco, Adoración ^c   Carracedo, Angel ^a   Ibáñez, Luisa ^c,d   Passiu, Marianna ^e   Provezza, Lisa ^e   Ramos Ruiz, Ricardo ^f   Ruiz, Borja ^b   Salado Valdivieso, Inés ^g   Velasco, Eladio A ^h   Figueiras, Adolfo ^a,i  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b HOSPITAL DE GALDAKAO   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITY OF VERONA   (Italy)

^f Toñi Martín Gallardo Genomics Unit   (Spain)

^g University of Valladolid   (Spain)

^h UNIVERSITY OF VALLADOLID   (Spain)

ⁱ CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYTOCHROME P450 2C9; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA FLANKING REGION; DRUG METABOLISM; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE MUTATION; GENETIC DIFFERENCE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; ITALY; MAJOR CLINICAL STUDY; PHARMACOGENOMICS; POPULATION GENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTHERN EUROPE; SPAIN; WILD TYPE;

5' FLANKING REGION; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; DATABASES, GENETIC; GENE FREQUENCY; GENETICS, POPULATION; HAPLOTYPES; HUMANS; ITALY; LINKAGE DISEQUILIBRIUM; LIVER; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; SPAIN;

EID: 70349682537     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2009.30     Document Type: Erratum

References (27)

1. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 342-3499.
2. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 1667-1671.
3. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: Ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54: 1257-1270.
4. Läpple F, von Richter O, Fromm MF, Richter T, Thon KP, Wisser H et al. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 2003; 13: 565-575.
5. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 1-16.
6. Ingelman-Sundberg M, Daly AK, Nebert DW. Human cytochrome P450 allele Hnomenclature. Avaliable from: URL: http://www.cypalleles.ki.se/CYP alleles/.
7. Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol Appl Pharmacol 2005; 207: 52-56.
8. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J Am Med Assoc 2002; 287: 1690-1698.
9. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-263.
10. Ingelman-Sundberg M, Sim SC, Gómez A, Rodríguez-Antona C. Influence of cytochrome P450 polymorphisms on drugs therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496-526.
11. Mas S, Crescenti A, Vidal-Taboada JM, Bergoñon S, Cuevillas F, Laso N et al. Simultaneous genotyping of CYP2C9*2, *3, 5′ flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis. Eur J Clin Pharmacol 2005; 61: 635-641.
12. Aynacioglu AS, Brockmöller J, Bauer S, Sachse C, Güzelbey P, Ongen Z et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48: 409-415.
13. Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 2003; 56: 653-657.
14. LLerena A, Dorado P, O'Kirwan F, Jepson R, Licinio J, Wong ML. Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. Pharmacogenomics J 2004; 4: 403-406.
15. Vianna-Jorge R, Perini JA, Rondinelli E, Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther 2004; 76: 18-26.
16. Morin S, Bodin L, Loriot MA, Thijssen HH, Robert A, Strabach S et al Pharmacogenetics of acenocoumarol pharmacodynamics. Clin Pharmacol Ther 2004; 75: 403-414.
17. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-1819.
18. Van der Weide J, Steijns LS, Van Weelden MJ, de Haan K. The effect genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001; 11: 287-291.
19. Ackermann E, Cascorbi I, Sachse C, Brockmöller J, Mrozikiewich PM, Roots I. Frequencies and the allelic linkage of CYP2C9 mutations in a German population, and the detection of a C/T mutation in intron 2 [abstract]. Eur J Clin Pharmacol 1997; 52: A71.
20. Ozawa S, Shoket B, McDaniel LP, Tang YM, Ambrosone CB, Kostic S et al Analyses of bronchial bulky DNA adduct levels and CYP2C9, GSTP1 and NQO1 genotypes in a Hungarian study population with pulmonary diseases. Carcinogenesis 1999; 20: 991-995.
21. Margaglione M, Colaizzo D, D́Andrea G, Brancaccio V, Ciampa A, Grandone E et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-778.
22. Yassar Ü, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F. Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254: 628-631.
23. Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 2001; 79: 841-847.
24. Shintani M, Ieiri I, Inoue K, Mamiya K, Ninomiya H, Tashiro N et al Genetic polymorphisms functional characterization of the 50-flanking region of the human CYP2C9 gene: In vitro and in vivo studies. Clin Pharmacol Ther 2001; 70: 175-182.
25. González JR, Armengol L, Solé X, Guinó E, Mercader JM, Estivill X et al. SNPassoc: An R package to perform whole genome association studies. Bioinformatics 2007; 23: 644-645.
26. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162-1169.
27. Excoffier L, Laval G, Scheneider S. Arlequín ver. 3.0: An integrated software package for population genetics data analysis. Evol Bioinform Online 2005; 1: 47-50.